Neurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
Follow NBIX
Neurocrine Biosciences, Inc. (NBIX) Piotroski F-score
Neurocrine Biosciences, Inc.'s Piotroski F-score for fiscal 2025 is 7 out of 9: 7 of nine tests of profitability, leverage and efficiency passed, down from 8 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 7 | (1.00) |
| FY2024 | 8 | 2.00 |
| FY2023 | 6 | 0.00 |
| FY2022 | 6 | 2.00 |
| FY2021 | 4 | (1.00) |
| FY2020 | 5 | (2.00) |
| FY2019 | 7 | 1.00 |
| FY2018 | 6 | 3.00 |
| FY2017 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 11.46% | 9.79% | Pass | 1 |
| Positive operating cash flow | 782.70m | 595.40m | Pass | 1 |
| Rising return on assets | 11.46% | 9.79% | Pass | 1 |
| Cash flow above net income | 304.10m | 254.10m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 3.39 | 3.40 | Fail | 0 |
| No new shares issued | 99,500,000 | 100,400,000 | Pass | 1 |
| Rising gross margin | 98.18% | 98.56% | Fail | 0 |
| Rising asset turnover | 0.69 | 0.68 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 7 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| UTHR United Therapeutics Corporation compare | 8 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 8 |
| ALKS Alkermes plc compare | 7 |
| NBIX Neurocrine Biosciences, Inc. | 7 |
| LNTH Lantheus Holdings, Inc. compare | 5 |
| ELAN Elanco Animal Health Incorporated compare | 5 |
| RDY Dr. Reddy's Laboratories Ltd compare | 4 |
| VTRS Viatris Inc. compare | 4 |
| HIMS Hims & Hers Health, Inc. compare | 4 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover